{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-05T12:13:32.668Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-05. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-05. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-05, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"ILMN\",\n  \"company\": \"Illumina, Inc.\",\n  \"investigation_summary\": \"Illumina is a dominant sequencing and array-based genomics platform company ($25B market cap) that has surged ~84% YTD to within 5% of its all-time high. Q1 FY2026 results beat on both EPS (+9% surprise at $1.15 vs $1.055 est.) and revenue, driven by NovaSeq X adoption acceleration, clinical sequencing demand, and early SomaLogic proteomics contribution following the January 2026 acquisition for ~$460M cash + contingent consideration. The stock is richly valued (forward P/E 28.4x, EV/EBITDA 23x) with elevated RSI at 74.9 into a July 30 earnings report that historically beats by 9-18%. Keith Meister's Corvex Capital remains a large shareholder but has been aggressively distributing shares into this rally. The stock lacks the mispricing element — it is fully valued at/near peak multiples, making any new long entry asymmetric-risk-unfavorable. However, with IV elevated from recent volatility and the stock range-bound near 52w high, income strategies (CC/strangle) are structurally viable.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"csp\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company generates ~$4.4B in annual revenue primarily from consumables (74% of product revenue, dominated by sequencing reagents) and instruments (11%), with services contributing 15%. It operates in research/academic (core), clinical oncology/translational, reproductive health, and agrigenomics markets. Key products include the NovaSeq X Plus production-scale sequencer (launched late 2023, enabling $200/genome human genome economics), MiSeq i100 benchtop system (launched 2024 with room-temperature reagents), and the DRAGEN bioinformatics platform for secondary analysis. On January 30, 2026, Illumina acquired SomaLogic from Standard BioTools for ~$460M in cash plus up to $75M milestones and a 2% royalty on NGS library prep kits — extending Illumina into proteomics as part of a multi-omics strategy. GRAIL (cancer screening) was spun off June 24, 2024; Illumina retains ~14.5% stake plus CVR obligations worth up to $1B every 12 years if certain milestones are met.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"Keith Meister (Corvex Capital)\",\n          \"role\": \"Director / 10%+ Owner\",\n          \"amount_usd\": 2500000,\n          \"date\": \"2026-05-28\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000101143826000371/xslF345X06/form4.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 2500000,\n      \"distinct_insider_buyers_90d\": 1,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 115000000,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-30\",\n      \"recent_eps_surprise_pattern\": \"4 consecutive positive beats: Q2 2025 +17.7%, Q3 2025 +14.7%, Q4 2025 +9.7%, Q1 2026 +9.0%. Pattern is narrowing but remains consistently positive.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"NovaSeq X Plus adoption accelerating — enables $200/genome; production-scale sequencing economics expanding TAM into population genomics programs and national biobanks\",\n          \"date_or_window\": \"Ongoing throughout 2026, driving consumables pull-through\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"fireflyGO automated oncology research platform (with SPT Labtech) launched May 28, 2026; first distributed whole-genome MRD kit announced May 28, 2026 — validated with Mayo Clinic, Bristol Myers Squibb at ASCO. New oncology software integrations with IDT xGen FFPE/cfDNA workflows\",\n          \"date_or_window\": \"May-June 2026 launches; early access ongoing\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-spt-labtech-unveil-fireflygo-163000407.html\",\n            \"https://finance.yahoo.com/sectors/healthware/articles/illumina-introduces-first-distributed-whole-131500045.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"acquisition\",\n          \"description\": \"SomaLogic acquisition closed January 30, 2026 — proteomics expansion; $460M cash + up to $75M milestone + 2% royalty. Goodwill of $171M and intangible assets of $186M (developed technology $158M at 9yr life) on preliminary allocation\",\n          \"date_or_window\": \"Integration ongoing throughout 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Ongoing risks: China unreliable entities list inclusion (impacting Greater China revenue); NIH funding reduction risk under Trump administration; tariff impacts from U.S.-China trade tensions. These are documented as material uncertainties in 10-K and Q1 2026 MD&A.\",\n          \"date_or_window\": \"Ongoing — no resolution date\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm\"\n          ],\n          \"directional_bias\": \"bearish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 FY2026 earnings July 30, 2026 after market close — consensus EPS $1.22 on $1.13B revenue; consistent positive surprise history (4 consecutive beats) supports continued beat potential\",\n          \"date_or_window\": \"July 30, 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000087/ilmn-20260430.htm\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 28.38,\n      \"sector_median_forward_pe\": 22,\n      \"ev_to_ebitda\": 23.2,\n      \"sector_median_ev_to_ebitda\": 16.5,\n      \"fcf_yield_pct\": 3.33,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Stock is fully valued-to-rich: 28x forward P/E vs ~22x sector median, EV/EBITDA of 23x vs ~16-17x peers. No discount to intrinsic value; stock has already re-rated significantly (+84% YTD) following the GRAIL spinoff resolution and NovaSeq X acceleration narrative. The bull case is largely priced in at current levels.\"\n    },\n    \"quality\": {\n      \"roic_pct\": 8.68,\n      \"gross_margin_trend_pp_yoy\": -0.7,\n      \"net_debt_to_ebitda\": 3.1,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 74.9,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 168.06,\n    \"ytd_return_pct\": 83.29,\n    \"from_52w_high_pct\": -5.16\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000124/ilmn-20260521.htm\",\n      \"key_takeaways\": [\n        \"Annual shareholders meeting May 21, 2026: all 9 director nominees elected. Notable: Keith Meister (Corvex Capital) re-elected with ~127M votes FOR; David P. King newly elected to board — strategic addition supporting clinical acceleration strategy. All proposals passed including Ernst & Young ratification and executive compensation advisory approval.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-09-18\",\n      \"2026-12-18\"\n    ],\n    \"iv_summary\": \"Near-term ATM IV elevated; stock has been volatile (Feb 2026 saw intraday swings of $15+ on tariff concerns). Put skew modest — market not aggressively hedging downside. Call OI concentrated at $175 (134 contracts), suggesting covered call writing interest or bullish targets being set around +4% from spot.\",\n    \"notable_skew_or_flow\": \"Options flow is net bullish per crude UOA: put/call ratio 0.31, net dollar bias $135K toward calls. Top open interest in calls at $175 strike (134 OI), then $150 and $160. Put OI led by $160 (42 contracts). No whale blocks detected — not a dramatic institutional positioning signal.\"\n  },\n  \"competitive_landscape\": \"Illumina holds an estimated 80%+ share of the global NGS market, with primary competitors being Thermo Fisher Scientific (Ion Torrent platform — smaller footprint), Oxford Nanopore Technologies (emerging long-read sequencing disrupting certain applications but not yet production-scale economics), Pacific Biosciences (HiFi long-read for specific applications), and Agilent/Microarray peers. The moat is primarily consumables lock-in: customers who purchase Illumina instruments are economically tied to proprietary reagent and flow cell consumption, creating sticky recurring revenue streams. SomaLogic acquisition extends into proteomics TAM adjacent to core genomics. Emerging threats include customer concentration risk (NIH-funded academic labs face potential funding cuts), China regulatory blacklisting risk reducing APAC/China market access, and tariff-driven supply chain costs.\",\n  \"key_risks\": [\n    \"China unreliable entities list inclusion — Greater China revenue declined $72M to $52M in Q1 2026; ongoing regulatory uncertainty could accelerate\",\n    \"NIH grant funding reductions under Trump administration: academic/government labs represent core customer base; demand reduction risk is material\",\n    \"Tariff impacts from U.S.-China trade tensions: explicitly cited as uncertainty in MD&A with cost mitigation efforts underway — unquantified but real exposure on supply chain and product pricing\",\n    \"Stock has run +84% YTD, currently 5% below 52-week high of $177.22; RSI overbought at 74.9 — entry risk is significant on a pullback\",\n    \"GRAIL CVR obligations: up to $1B payments every 12 years if milestones achieved; market may underappreciate contingent liability duration and magnitude\",\n    \"Debt load elevated (net debt/EBITDA ~3x); $499M term notes due in near-term create refinancing risk exposure\",\n    \"Keith Meister/Corvex Capital — large shareholder aggressively distributing stock into this rally ($115M+ sold May 28 - June 1, 2026 at prices below current levels)\"\n  ],\n  \"what_the_market_might_be_missing\": \"Nothing material. The GRAIL disposal (resolving FTC overhang), NovaSeq X adoption ramp, and SomaLogic proteomics expansion are all known and reflected in the price re-rating (+84% YTD). Market is not missing a fundamental thesis — the stock simply ran because the prior headwinds (FTC litigation, GRAIL mandatory divestiture) resolved. The one structural edge worth noting: Illumina's IP portfolio expansion ($50M IP acquisition Q1 2026 adding developed technology at ~14-year life) and DRAGEN software ecosystem lock-in represent a durable competitive moat that may be underweighted in near-term earnings models relative to its long-term value — but this is incremental, not an asymmetric mispricing at current multiples. SomaLogic integration execution risk (proteomics market development) is real and unquantified.\",\n  \"anti_signals_present\": [\n    \"concentration\",\n    \"dilution\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Illumina FY2025 10-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm\"\n    },\n    {\n      \"label\": \"Illumina Q1 FY2026 10-Q\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm\"\n    },\n    {\n      \"label\": \"Q1 FY2026 Earnings Release 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000087/ilmn-20260430.htm\"\n    },\n    {\n      \"label\": \"Annual Meeting Results 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000124/ilmn-20260521.htm\"\n    },\n    {\n      \"label\": \"Keith Meister / Corvex Form 4 (May 28, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000101143826000371/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Patricia Leckman SVP Form 4 (June 2, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000132/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"ILMN Stock Jumps 98.7% — Yahoo Finance catalyst summary\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/ilmn-stock-jumps-98-7-145200538.html\"\n    },\n    {\n      \"label\": \"Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthware/articles/illumina-oncology-launches-put-product-160513872.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-05T12:14:06.010Z",
      "raw_content": "<think>The dossier is for Illumina, Inc. (ILMN), a $25B market cap company.\nScout's verdict: `range_bound_or_income`.\nScoring inputs:\n- Smart Money: 1 insider buyer (Keith Meister, Corvex) with $2.5M in last 90 days. Material insider selling $115M in last 90 days. (Penalty: -10 pts for selling > buying). Score: 2 (distinct_insider_buyers_90d = 1, amount $2.5M < $5M, no CEO/CFO, no 13F, no politician). Wait, scoring rubric: 10 pts if 3+ distinct buyers totaling >= $500K. Here only 1 buyer. So 0 pts for the base. Actually, the rubric says: \"10 pts if 3+ distinct insiders... totaling >= $500K\". I'll give 0.\n- Options Flow: IV elevated. Put/call ratio 0.31, net dollar bias $135K toward calls. Call OI at $175. No whale blocks. Score: 1 (net dollar bias > 30%? $135K is small, but ratio is 0.31. I'll give 1 or 2. Let's say 2).\n- Catalyst: Earnings July 30, 2026. Last 4 quarters EPS surprise > 0%. Guidance raise in last 90d. Product launches (fireflyGO, SomaLogic integration). Score: 10 (earnings within 90d + 4 beats) + 5 (guidance raise) + 5 (product) = 20. Cap 25.\n- Mispricing: Forward P/E 28.4 vs sector 22. EV/EBITDA 23 vs 16.5. FCF yield 3.33%. No discount. Score: 0.\n- Quality: ROIC 8.68%, gross margin -0.7pp, net debt/EBITDA 3.1. Score: 0.\n- Technical: Above 50/200DMA. RSI 74.9 (overbought). MACD bullish cross. 12-1 momentum null. Score: 3 (above DMAs) + 1 (MACD cross) = 4.\nTotal Score: ~0 + 2 + 20 + 0 + 0 + 4 = 26.\nAnti-signals: \"concentration\", \"dilution\" (maybe from GRAIL CVR or SomaLogic earnout?). Also, material insider selling $115M vs $2.5M buying.\nRisk Class: Core (> $5B).\nThresholds for Core: < 45 Skip.\nAlso, anti-signal gate: \"material insider SELLING > BUYING in dollars\" -> -10 pts.\nThe dossier explicitly says: \"Stock is fully valued-to-rich... No discount to intrinsic value... entry risk is significant on a pullback.\"\nScout verdict: range_bound_or_income.\nGiven the score is well below 45, and the anti-signal of massive insider selling ($115M) vs tiny buying ($2.5M), plus the stock being richly valued and overbought (RSI 74.9), this is a clear skip.\nI will draft a skip JSON.\nCheck scoring breakdown carefully:\nSmart money: 0 (1 buyer, $2.5M, massive selling)\nOptions flow: 2 (net bullish bias, elevated IV)\nCatalyst: 15 (earnings + guidance raise)\nMispricing: 0 (richly valued)\nQuality: 0 (ROIC < 15%, margin declining, debt > 2x)\nTechnical: 4 (above DMAs, MACD cross, but RSI high)\nTotal: ~21.\nReason: Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The dossier explicitly notes the stock has already re-rated +84% YTD with the bull case priced in; no mispricing or asymmetric structure exists at current levels.\nI will output the skip JSON.\nWait, let's verify the scoring rubric for Smart Money:\n\"10 pts if 3+ distinct insiders... totaling ≥ $500K\" -> 0 pts.\n\"Penalty: −10 pts if material insider SELLING > BUYING in dollars\" -> -10 pts.\nSo Smart Money score is 0.\nOptions Flow: 2 pts.\nCatalyst: 15 pts.\nMispricing: 0 pts.\nQuality: 0 pts.\nTechnical: 4 pts.\nTotal: 21.\nMatches skip threshold.\nI will produce the JSON.\nCheck format:\n{\n  \"skip\": true,\n  \"score\": 21,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.\"\n}\nAll good.\nOne minor thing: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I'll just put 0 for smart_money as it's capped at 0 anyway, or -10? The rubric says max 25, but doesn't specify floor. I'll just put 0 for simplicity, or -10. I'll stick to 0.\nActually, the rubric says \"max 25\", so scores can't go negative usually, but I'll just output 0.\nI will ensure the JSON matches exactly.\nProceed. \nLet's double check the catalyst score: \"10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\" -> 10. \"5 pts: recent guidance raise (last 90 days)\" -> 5. Total 15.\nTechnical: \"3 pts: above both 50DMA and 200DMA\" -> 3. \"1 pt: MACD bullish cross in last 30 days\" -> 1. Total 4.\nOptions: \"2 pts: net_dollar_bias_pct > 30\" -> The dossier says \"net dollar bias $135K toward calls\". It doesn't give a percentage, but put/call ratio is 0.31, which is very bullish. I'll give 2.\nTotal: 21.\nSkip is correct.\nOutput matches requirements.\nDone. \nOne detail: \"risk_class\" is not needed in skip output.\n\"ONLY ONE STRUCTURE TYPE.\" -> Skip output doesn't need it.\n\"OUTPUT ONLY VALID JSON.\"\nReady. \nProceeds. \nOutput Generation. \n(Self-Correction/Refinement during thought)\nWait, the prompt says: \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I will just put 0 for smart_money to be safe, or -10. It doesn't matter much for a skip. I'll stick with 0.\nThe reason should be 1-2 sentences.\nAll good. \nOutput matches. \nProceeds. \n[Output Generation] -> JSON. \n```json\n{\n  \"skip\": true,\n  \"score\": 21,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.\"\n}\n```\nMatches perfectly. No extra text.\nDone. \nProceeds. \n(Self-Correction/Verification during generation prep)\nCheck date rules: Not applicable for skip.\nCheck structure: Exact match.\nCheck score breakdown keys: exact match.\nCheck reason length: 2 sentences.\nAll good. \nOutput matches. \n[Done] \n`\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 21,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 21,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 21,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 33342,
  "stop_reason": "stop",
  "completed_at": "2026-06-05T12:14:06.010Z"
}